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ABSTRACT:  
Background: External Beam Radiotherapy is essential in the management of locally 
advanced cervical cancer (LACC).  Generally, VMAT is thought to achieve higher 
conformity to the Planned Target Volume (PTV) and better sparing of organs at risk 
(OAR) when compared to 3D-CRT. This study focused on these principles as it applied 
to treatment and potential toxicity in the management of LACC.   
 
Aim: To compare dosimetric parameters between VMAT and 3D-CRT in the 
management of LACC.  
 
Setting: The study analysed patients treated at Groote Schuur Hospital between May 
and December 2017. 
 
Method: A non-randomized comparative retrospective study. EBRT plans for 3D-CRT 
and VMAT were generated and data on treatment parameters for PTV D50%, Dmax, 
Dmean, Conformity Index (CI), Homogeneity Index, Treated Volume (TV), Irradiated 
Volume (IV) and OAR constraints; femoral heads, bladder, bowel bag, rectum and 
bone marrow were collected. 
 
Results:  Of the 45 patients assessed, VMAT showed significantly lower treatment 
parameter values for CI (1.09 vs 1.49; p<.001) and TV (1613.1 cm3 vs 2230.3 cm3; p< 
.001) whereas, 3D-CRT showed lower Dmax (48.1Gy vs 49.2Gy; p<.001) and IV 
(10652.2 cm3 vs 14618.1 cm3; p<.001). OAR doses revealed a decreased maximum 
dose with VMAT to both femoral heads, a lower V45 for bowel bag (182.3 cm3 vs 411.3 
cm3; p<.001) and a lower V40 for bone marrow (19.1% vs 38.7%; p< .001) and rectum 
(88.5% vs 96%). A reduced 3D-CRT dose was noted for bladder Dmax (47.4Gy vs 
48.3Gy; p< .001).  
 
Conclusion: VMAT offered a superior dosimetric option, with better OAR dose 
sparing and optimal tumour dosimetry.   
 
Keywords: Cervical cancer, VMAT, 3D-CRT, radiation therapy, dosimetry 
Corresponding Author: vishambhagaloo@gmail.com 





The global, yearly incidence of cervical cancer in 2012 was 528,000 with an annual 
death rate of 266,0001. It is the fourth most common cancer in women worldwide2,3 
with 85% occurring in developing countries, and the leading cause of death1,4. In South 
Africa cervical cancer remains the third most common cancer diagnosed with an 
estimated 7735 new cases in 2012 and 4,248 deaths5. In developing countries, 
patients usually present with locally advanced stage disease and are treated with 
concurrent chemotherapy and external beam radiotherapy (EBRT) followed by 
brachytherapy. This study seeks to compare dosimetric values for Volumetric 
Modulated Arc Therapy (VMAT) to 3-D Conformal Radiotherapy (3D-CRT), both 
external beam radiotherapy options in the management of locally advanced cervical 
cancer (Stage 1B2- IVA) at Groote Schuur Hospital.  
 
Purpose of the study 
The primary objective: 
• To determine whether VMAT is dosimetrically superior to 3D-CRT in the 
treatment of locally advanced cervical cancer at Groote Schuur Hospital. 
 
Primary Research Hypothesis: 
• VMAT is dosimetrically superior to 3D-CRT. 
(a) Dmax to organs in series is reduced in VMAT compared to 3D-CRT. 
(b) VMAT improves Conformity Index (CI) and Homogeneity Index (HI) to the 
Planned Treatment Volume (PTV) when compared to 3D-CRT. 
(c) Dmean to organs in parallel are reduced in VMAT when compared to 3D-CRT. 
(d) Irradiated volume (IV) is increased in VMAT when compared to 3D-CRT. 
(e) Treated volumes (TV) are reduced in VMAT compared to 3D-CRT. 
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Background 
Cervical cancer remains one of the most concerning cancers for women in developing 
countries as it represents the leading cause of death by a malignant condition. In May 
2017 VMAT was added as a treatment option for locally advanced cervical cancer 
(LACC) at Groote Schuur Hospital. Multiple studies on Intensity Modulated 
Radiotherapy (IMRT) have suggested a decrease in gastrointestinal and 
haematological toxicities with preliminary outcomes suggesting similar tumour control 
and survival (6-8). To date, there have been no studies to investigate the change from 
3D-CRT to VMAT at our institution or similar low-middle income centres. This study 
seeks to provide dosimetric data comparing EBRT options; 3D-CRT and VMAT in the 
treatment of LACC.  
 
Methodology 
This is a non-randomized comparative retrospective study. The patients who 
presented to Groote Schuur Hospital with LACC as staged using FIGO 2009 between 
May 2017 to December 2017 and completed treatment will form the study population. 
The patients selected would have completed treatment using VMAT and concurrent 
chemotherapy followed by brachytherapy. The selected patients who meet the 
inclusion criteria will have a second radiotherapy plan generated using 3D-CRT by an 
experienced radiotherapy planner. The plans generated will be evaluated by two 
Radiation Oncologist and accepted or rejected based on plan evaluation criteria. Plans 
are deemed acceptable when the PTV is covered between 95-107% of the dose, OAR 
are within tolerance as compared to QUANTEC guidelines and no hotspots (volume 
outside PTV >100% PTV dose + 15mm size). Rejected plans will be re-planned and 
analysed again. The 3D-CRT plans will be used for study analysis only, as these 
patients have all completed treatment. The plans will be compared with special 
emphasis on D2%, D98%, D50%, Dmax, Dmean, CI, HI, separation, TV and IV. The data will 
be collected on REDCap database with de-identification of patient information. The 
results will guide as to dosimetric superiority (Minimized OAR toxicity and superior 
PTV coverage) between 3D-CRT and VMAT at Groote Schuur Hospital for the 
management of LACC. 
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Characteristics of the study population 
The study population will include all patients with locally advanced cervical cancer who 
received definitive chemotherapy and radiotherapy followed by brachytherapy at 
Groote Schuur Hospital between May 2017 to December 2017.  
 
Inclusion Criteria: 
• Minimum age of 18 years. 
• Advanced staged disease (FIGO 2009). 
• Performance Status (ECOG)- 0-2. 
• Received treatment between May 2017 to December 2017. 
• HIV positive and negative disease. 
 
Exclusion Criteria: 
• Connective tissue disorders. 
• Previous pelvic radiotherapy. 
• Performance status (ECOG) 3-4. 
• Post-op early stage cervical cancer who qualify for RT 
 
 
Recruitment and enrolment 
The patient population was selected from those confirmed with locally advanced 
cervical cancer at Groote Schuur Hospital and received treatment between May 2017 
to December 2017. Once the inclusion criteria were met the patient was included in 
the study. Information regarding dosages will be retrieved from the planning system 
and all other data from medical records. This information will be used to substantiate 
the dosimetrically superior option. 
 
8 | P a g e  
 
Research procedures and data collection methods 
A data collection form (Appendix iii) will be generated using the REDCap database 
including general demographics and de-identified to maintain privacy. The dosimetric 
values identified will be collected from the planning system for 3D-CRT and VMAT. 
Statistical analysis will follow to determine the significance of the data gathered.  
 
Data analysis 
The dosimetric values gathered will be analysed using a Shapiro-Wilk test to 
determine if the data is normally distributed. The result then determines if a simple 
paired T-test or a two tailed Wilcoxon Signed Rank Test will be used to determine the 
statistical significance of the data collected. Statistical significance was accepted when 
P<0.05.  
 
Description of Risks and Benefits 
 
Potential Risks and Discomforts: 
This is a retrospective dosimetric comparative study with patients who have completed 
treatment with VMAT for locally advanced cervical cancer and will now have a 
simulated 3D-CRT plan. The plans will be compared with the parameters outlined 
above. There will be no direct patient interaction and treatment has been completed 
in all participants, as such there is minimal risk. 
 
Potential Benefits: 
The study will provide evidence on the dosimetrically superior option for the treatment 
of locally advanced cervical cancer at Groote Schuur. 
 
Informed Consent: 
Consent will not be obtained as this is a retrospective study and does not directly affect 
care. 
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Privacy and Confidentiality: 
The data collected will be stored on the REDCap database under password protection 
with access granted to the principal investigators. The data stored will be de-identified 
to ensure privacy and confidentiality. 
 
Reimbursement for Participation: 
There will be no reimbursement for participation as the study has no direct interaction 
with patients. 
What happens at the end of the study? 
It is the hope that the data analysed will be statistically significant and as such provide 
evidence to the dosimetrically superior option for the treatment of locally advanced 
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The literature review was undertaken to provide a background on locally advanced 
cervical cancer (LACC), while proving data on its management with special emphasis 
on external beam radiotherapy. The data analysed will hopefully afford a history of the 
advancements in radiotherapy while assessing its dosimetric and clinical effect. 
Furthermore, comparisons between 3Dimensional-Conformal Radiotherapy and 
Volumetric Modulated Radiotherapy will be highlighted, focusing on pros and cons. It 
is hoped that the review will outline the limited information available to date, including 




LITERATURE SEARCH STRATEGY: 
 
To retrieve the widest variety of information and published articles we used Google 
Scholar, Pub Med, Journal articles, Web sites, and Google. Search words utilised 
included; Locally Advanced Cervical Cancer (LACC), 3Dimensional- Conformal 
Radiotherapy (3D-CRT), Volumetric Modulated Arc Therapy (VMAT), dosimetric 
benefit of VMAT vs 3D-CRT in LACC, side effects of VMAT vs 3D-CRT, Intensity 
Modulated Radiotherapy (IMRT), Lower and Middle Income Countries (LMIC).  
 
The articles generated were reviewed for applicability and relevance to the given topic. 
Additionally, the limited data found suggested a definite need for further studies with 
the greatest issue arising from small study populations. Meta-analyses and some 
retrospective studies supplied the foundation of the information, but less robust 
observational studies were considered once their analysis suggested credible, 











In 2018, the World Health Organisation (WHO)  published statistics stating that 
cervical cancer was the fourth most frequent cancer in women globally, representing 
6.6% (570,00 cases) for that year, of which 90% of deaths occurred in low- and middle-
income countries (LMIC).(1) Professor Denny et al., when reviewing cervical cancer in 
Africa, stated that 267.9 million women aged 15 years and older are at risk of 
developing cervical cancer. Of these, 80,000 are diagnosed with cervical cancer 
yearly, and more than 60,000 die from the disease.(2) The highest rates of cervical 
cancer in Africa, based on the Age Standardized Incidence Rate (ASIR > 40/100,000), 
are found in Eastern and Southern Africa. In Southern Africa, the highest percentages 
were found in Lesotho and Swaziland followed by South Africa mainly as a result of 
inadequate screening programmes.(2) The National Cancer Registry of South Africa 
suggested that cervical cancer is the 3rd most common cancer among South African 
women with a 1 in 42 lifetime risk of cervical cancer.(3) In 2014, South Africa registered 
5735 new cases of cervical cancer representing 15.17% of all female cancers.(3) Over 
60% of the patients diagnosed with cervical cancer ranged within the 35 to 60 age 
group, undoubtedly affecting the female work force in South Africa. As such, 
appropriate, standardised and effective treatment with minimal toxicity is imperative in 
the management of early and locally advanced cervical cancer (LACC).   
 
The European Society of Medical Oncologist (ESMO) describe locally advanced 
cervical cancer as those Staged between IB2 and IVA using the 2009 International 
Federation of Gynaecology and Obstetrics (FIGO) classification.(Appendix iv) To date, 
there is limited data on stage of diagnosis in South Africa as updated staging registries 
are lacking. From our experience at Groote Schuur Hospital (GSH), observational 
estimates suggest a higher percentage of patients present with locally advanced 
disease. This is in direct contrast to international publications in which patients present 
with earlier stage disease, mainly due to robust screening programmes.(4) In 1997 
Landoni et al compared surgery vs radiotherapy in the treatment of FIGO Stage IB 
(most <4cm) or IIA cervical cancers.(5) The study population showed equal efficacy of 
treatment with External Beam Radiotherapy (EBRT) or surgery with the radiotherapy 
group having far less toxicity. On further analysis the study was heavily dominated by 
resectable early stage disease and it is believed that in more advanced disease a 
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definitive benefit would have been revealed for EBRT over surgery. Within 2 years 
following Landoni’s et al. study , 3 randomised studies were published showing the 
benefit of combining chemotherapy with radiotherapy in the management of LACC .(6-
8) In the analysis done by Rose et al for the Gynaecology Oncology Group (GOG), 526 
women were randomly assigned to receive cisplatin-based chemotherapy or 
hydroxyurea.  The combination of cisplatin-based chemotherapy led to an 
improvement in survival and progression free survival when compared to hydroxyurea. 
Today, LACC is  managed definitively with EBRT and concurrent chemotherapy 
followed by brachytherapy.(9) EBRT is indicated in approximately 60% of patients with 
cervical cancer treated with curative intent as seen in the article comparing VMAT to 
3D-CRT by Delaney et al .(10) Surgical intervention is limited to early stage disease in 
modern practice, mainly Stage 1A and 1B1. 
 
External Beam Radiotherapy has evolved over time in the management of cancer with 
greater emphasis placed on improving the therapeutic index. The therapeutic index is 
defined as a relationship of tumour control probability and normal tissue complication 
probability at unique doses of radiation.(11) Initially, LACC was treated with 
conventional radiotherapy, utilising bony structures as landmarks. However, this has 
been replaced with more conformal radiotherapy using CT based images. 3D-CRT 
emerged as the EBRT treatment of choice for LACC in the late 1990’s offering better 
target coverage and reduced bladder radiation. This was shown in the study of 20 
patients with Stage IIB and IIIB comparing beams eye view planning to four field box 
by Gerstner et al.(12) While noted to have a small patient population, the study showed 
a 20% geographical miss when using conventional treatment with an increased 
volume of bladder and bowel bag in the treated volume. In 2013, a small dosimetric 
study done by Goswami et al. and published in the South Asian Journal of Oncology 
compared conventional radiotherapy to conformal radiotherapy. In the study, 
Goswami et al. suggested that 3D-CRT gives better coverage improving local control 
and survival at the expense of larger fields and similar dose homogeneities.(13) 3D-
CRT is the most widely used method of EBRT(14) but has been associated with 
increased toxicity including genitourinary symptoms, gastrointestinal symptoms and 
bone marrow suppression particularly when combined with concurrent 
chemotherapy.(15) At GSH all patients treated with curative intent receive concurrent 
chemotherapy, increasing possible toxicities. It is with this concern in mind that 
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Volumetric Modulated Arc Therapy (VMAT), a type of Intensity Modulated 
Radiotherapy (IMRT), was considered to improve dosimetric optimisation and 
minimise toxicities for patients treated with EBRT for LACC. 
 
In 2003, S. Webb from the Royal Marsden NHS, London described IMRT as “a form 
of inverse planning that delivers radiation to the patient via fields that have non-uniform 
radiation fluence”.(16) The University of California, San Francisco Department of 
Radiation Oncology defines inverse planning “as a method of radiation treatment 
planning where one starts with the desired dose distribution, or clinical objectives, and 
then determines the treatment parameters that will achieve it.” VMAT is a form of IMRT 
combining variable dose rates and gantry speeds, a single gantry motion and dynamic 
multi-leaf collimation.(17) Numerous studies across different primary cancer sites 
suggest that VMAT may potentially offer a more conformal dose around tumour, 
improve avoidance of organs at risk, minimise toxicity and when necessary, allow for 
dose escalation.(18-20) Taking into account these principles, studies have been 
designed to compare the dosimetric and clinical benefit of VMAT to 3D-CRT in the 
management of LACC. 
 
Appropriate tumour coverage is imperative in mitigating the possibility of residual 
disease post treatment and reducing the possibility of local recurrence. This will 
undoubtedly result in improved overall survival. Mundt et al. studied whole pelvic 
radiotherapy with IMRT in 40 patients with gynaecological cancers and found that 
IMRT offered excellent Planned Target Volume (PTV) coverage. They showed that on 
average 98.1% of the PTV received the prescription dose. Additionally, the average 
percentage of the PTV receiving 110% and 115% of the prescription dose was 9.8% 
and 0.2% respectively. (21) The study, while under powered with a small population 
size, did not directly compare 3D-CRT to IMRT. As such, the findings can only be used 
as stand-alone data, and not a direct comparison of tumour control dosimetric 
superiority. In 2008, Taylor et al. examined the dosimetric differences among 
conventional radiotherapy, 3D-CRT and VMAT for 40 women. The study showed 
optimal tumour dosimetry with IMRT and allowed dose painting and dose escalation 
when compared to 3D-CRT. OAR toxicity was also reduced as VMAT allowed sparing 
of the rectum and bladder. (22) Chen et al. in 2007 compared 4 field box conventional 
radiotherapy to IMRT in patients with cervical cancer post hysterectomy. 68 patients 
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with similar pathological findings were assigned to either IMRT or 4 field box and 
followed up for 4 years to assess toxicity and tumour control. The results suggested 
that IMRT offered similar locoregional control while allowing greater tolerance to 
chemoradiotherapy. Another study done by Lukovic et al. showed that despite treating 
a larger volume, 4 field box technique is less homogenous and provides inferior 
coverage of the PTV compared to VMAT.(23) It is noted that both studies previously 
mentioned, examined the effect of radiotherapy in post-operative patients and not 
LACC. However, both authors are of the belief that the effect of radiotherapy in LACC, 
while not exact, will have many similarities to the patients in their study groups. Kam 
et al. showed that with increasing conformity, dose escalation was now safe and 
feasible, maximising tumour dose and allowing for selective dose escalation.(24)These 
studies suggest the prospect of offering improved coverage with the possibility of 
localised dose escalation may further enhance the therapeutic effect of VMAT when 
compared to 3D-CRT.   
 
The incidence and severity of radiation toxicity to OAR are multifactorial. These factors 
include the volume of tissue treated, dose received and the technique for delivery of 
radiation therapy. IMRT, with theoretical benefit for improving OAR sparing, was then 
examined in numerous trials to minimise the most common toxicities associated with 
LACC radiotherapy; Genitourinary (GU), Gastrointestinal (GU) and Haematological.(25, 
26) Mell et al reviewed 83 patients with LACC between 2011 to 2015 to determine if 
IMRT reduced haematological and GI toxicity when given with concurrent 
chemotherapy. The phase 2 study revealed a clinical benefit for both acute GI and 
haematological toxicities with promising therapeutic outcomes when the radiation 
dose was lowered. This phase 2 multicentre study analysed a diverse population but 
was limited by patient numbers and included both post resection and radical patients. 
Additionally, the data compared Image guided IMRT vs IMRT and comparison with 
conventional RT was based on recorded data.(27) Hasselle et al. reviewed 111 patients 
who were treated with IMRT and showed low toxicity and favourable outcomes, 
supporting its safety and efficacy in the treatment of cervical cancer.(25)This article had 
a larger study population improving its statistical strength. However, there was no 
direct comparison to 3D-CRT and as such the result must be analysed with this fact in 
mind. Radiation Therapy Oncology Group (RTOG) 1203 compared IMRT to 3D-CRT 
radiotherapy in cervical cancer and the results showed significantly lower scores for 
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gastrointestinal and urinary toxicity when using IMRT.(28) The study utilised the 
Expanded Prostate Cancer Index Composite (EPIC) to compare toxicities. EPIC is a 
questionnaire filled by patients on completion of treatment and subsequent follow ups 
to determine the clinical effect of treatment on their quality of life.  The mean EPIC 
bowel score declined 23.6 points in the 3D-CRT group and 18.6 points in the IMRT 
group while the urinary score declined 10.4 points in the standard RT group and 
5.6 points in the IMRT group. A larger decline from baseline suggested a poorer 
tolerance to treatment.  
 
Multiple studies have also evaluated GI and GU toxicity, suggesting an improvement 
in both acute and chronic toxicities when IMRT was compared to 3D-CRT. (25, 29, 30) 
Gandhi et al. reviewed 44 women between 2010 and 2012 who received 50.4Gy in 28 
fractions with either whole pelvic IMRT or conventional radiotherapy. For an average 
22 months, the patients were followed up and the results revealed comparable clinical 
outcomes with significantly less toxicity using IMRT when compared to 3D-CRT.(29) A 
retrospective study done in 2011 assessed 109 patients with LACC to determine the 
toxicity and tumour control associated with IMRT treatment. They were followed up for 
a median of 32.5 months and the results suggested the treatment regimen were well 
tolerated with favourable acute and late toxicity.(30) Naik et al. also examined 40 
patients equally distributed into two arms, comparing 3D-CRT to VMAT in the 
management of LACC. The results showed better conformity with reduction in dose to 
D35 and D50 for the bladder and rectum respectively, as well as a reduction in V45 for 
small bowel and V20 for bone marrow. This dosimetric benefit translated into a 
reduction in toxicity for both GI and GU systems, with no clinical difference found with 
bone marrow dose. The final analysis suggested IMRT plans were superior to the 3D-
CRT in reducing the volume receiving high doses in the bladder, rectum and bowel.(31) 
Further OAR sparing was noted in RTOG 418, a phase II study that looked at 83 
patients with cervical and endometrial cancer treated with IMRT alone. IMRT was 
associated with lower rates of haematological toxicities with a lower V40 volume and 
higher rates of cisplatin use when compared to 3D-CRT.(32) Additionally, the study by 
Brixey et al compared women receiving EBRT, either 3D-CRT or IMRT between 2000 
to 2001 to determine the haematological effect. 36 patients treated with IMRT were 
compared to 88 patients receiving 3D-CRT with similar volume delineation, dose 
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prescriptions and chemotherapy. The final results showed that IMRT lowered 
haematological toxicities and offered improved sparing  when used, compared to 3D-
CRT, to treat gynaecological malignancies.(26) Treatment which offers greater OAR 
sparing and minimises clinical toxicities are likely to improve compliance which affects 
tumour control and outcome. (33) 
  
While the studies listed above have suggested IMRT to be a superior dosimetric and 
clinical option, others have not shown this superiority and questioned its benefit. Yang 
et al. systematic review of gynaecological cancers in 2012, suggested that IMRT did 
not differentially affect the average percent volumes receiving a set dose to the bone 
marrow or bladder.(34) Also, a retrospective multi-centre study done in 2014 by Erpolat 
et al. proposed that while IMRT offers a dose reduced bone marrow volume, the 
clinical benefit was not found to be significant. The patient population follow up showed 
no difference between the two techniques, VMAT versus 3D-CRT, for acute or chronic 
haematological toxicity.(35)  
 
With the advent of VMAT additional issues regarding target definition, patient and 
target immobilisation, tissue deformation and reproducibility remain to be validated. 
(35-37) Lim et al. published a phase 2 article with expert opinion on CTV definition and 
contouring for patients being treated with IMRT for cervical cancer. 19 experts in the 
field agreed on guidelines which would hopefully synchronise contouring volumes 
while taking into consideration the specialised nature of IMRT contouring.(36)  
 
Although minimising the treated volume limits OAR toxicity, this may also increase the 
possibility of geographical miss, as inter and intra fraction organ motion may not be 
fully encompassed. Jadon et al. reported a systemic review in which this motion was 
examined and showed the greatest variability of the uterus ranging from 5 mm to 
40mm.(38) This variation in motion was not covered in IMRT (36) contouring guidelines 
as suggested and poses a serious issue when considering tumour control. However, 
with improved imaging localisation, such as daily kilovoltage cone beam CT as 
compared to megavoltage orthogonal images, tumour localisation, deformation and 
reproducibility may be minimised. The study done by Ahmad et al. in 2012 posited that 
pelvic rotations are large and should not be ignored. As a result, corrections with 6D 
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Studies comparing conventional techniques to Volumetric Modulated Arc Therapy in 
the management of locally advanced cervical cancer (LACC) are scarce, outdated and 
patient populations are small. To the best of our knowledge, there are no published 
articles in South Africa comparing these two modalities in the management of LACC. 
This study aims to provide local data that will hopefully clarify the dosimetrically 
superior option between these two approaches and support the switch to VMAT at our 
institution. We also hope to compare our data to international studies to determine if 
our results are comparable and if further optimisation of our techniques may be 
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VOLUMETRIC MODULATED ARC THERAPY (VMAT) VERSUS 3D CONFORMAL 
RADIOTHERAPY (3D-CRT) IN THE TREATMENT OF LOCALLY ADVANCED CERVICAL 
CANCER. A SINGLE INSTITUTION, COMPARATIVE DOSIMETRIC STUDY. 
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Background: External Beam Radiotherapy is essential in the management of locally 
advanced cervical cancer (LACC).  Generally, VMAT is thought to achieve higher 
conformity to the planned target volume (PTV) and better sparing of organs at risk (OAR) 
when compared to 3D-CRT. This study focused on these principles as it applied to 
treatment and potential toxicity in the management of LACC.   
Aim: To compare dosimetric parameters between VMAT and 3D-CRT in the management 
of LACC.  
Setting: The study analysed patients treated at Groote Schuur Hospital between May and 
December 2017. 
Method: A non-randomized comparative retrospective study. EBRT plans for 3D-CRT 
and VMAT were generated and data on treatment parameters for PTV D50%, Dmax, Dmean, 
conformity index (CI), homogeneity index, treated volume (TV), irradiated volume (IV) and 
OAR constraints; femoral heads, bladder, bowel bag, rectum and bone marrow were 
collected. 
Results: Of the 45 patients assessed, VMAT showed significantly lower treatment 
parameter values for CI (1.09 vs 1.49; p<.001) and TV (1613.1 cm3 vs 2230.3 cm3; p< 
.001) whereas, 3D-CRT showed lower Dmax (48.1Gy vs 49.2Gy; p<.001) and IV (10652.2 
cm3 vs 14618.1 cm3; p<.001). OAR doses revealed a decreased maximum dose with 
VMAT to both femoral heads, a lower V45 for bowel bag (182.3 cm3 vs 411.3 cm3; p<.001), 
and a lower V40 for bone marrow (19.1% vs 38.7%; p< .001) and rectum (88.5% vs 96%). 
A reduced 3D-CRT dose was noted for bladder Dmax (47.4Gy vs 48.3Gy; p< .001).  
Conclusion: VMAT offered a superior dosimetric option, with better OAR dose sparing 
and optimal tumour dosimetry.   
 
Keywords: Cervical cancer, VMAT, 3D-CRT, radiation therapy, dosimetry 
Corresponding Author: vishambhagaloo@gmail.com 
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INTRODUCTION 
Globally, cervical cancer is the fourth most frequent cancer in women, representing 
6.6% (570,00 cases) in 2018, of which 90% of deaths occur in low- and middle-income 
countries.(1) In 2014, South Africa registered 5735 new cases of cervical cancer, 
representing 15.17% of all female cancers, and the third most common cancer in 
women.(2) In South Africa, data is limited regarding stage of presentation, however at 
Groote Schuur Hospital (GSH) a higher percentage of the patients treated for cervical 
cancer, present with locally advanced disease. Locally advanced cervical cancer 
(LACC) (Stage 1B2- IVA (FIGO 2009)) is associated with a poorer prognosis with 5-
year survival rates of 58% in Stage IIB, 30% in Stage III and 16% in Stage IVA.(3) 
Cervical cancer continues to affect middle age females and has been associated with 
numerous socioeconomic factors especially in lower middle-income countries.(4) 
Considering these factors, appropriate, beneficial, minimally toxic and proven 
efficacious  treatment is imperative.  
 
LACC is managed definitively with External Beam Radiotherapy (EBRT) and 
concurrent chemotherapy followed by brachytherapy.(5) EBRT is indicated in 
approximately 60% of patients with cervical cancer treated with curative intent (6) as 
surgical intervention is limited to early stage disease, mainly Stage 1A and 1B1. 3D 
Conformal Radiation (3D-CRT) is the most widely used method of EBRT (7) but has 
been associated with significant toxicity including genitourinary symptoms, 
gastrointestinal symptoms and bone marrow suppression, particularly when combined 
with concurrent chemotherapy. (8) At GSH, all LACC patients treated radically with 
curative intent, receive concurrent chemotherapy, with radiotherapy increasing 
possible toxicities. It is with this concern in mind that Volumetric Modulated Arc 
Therapy (VMAT) was considered to improve dosimetric optimisation and potentially 
minimise toxicity for patients treated with EBRT for LACC. 
 
VMAT is a form of intensity-modulated radiation therapy (IMRT) linking together 
variable dose rates and gantry speeds, a single gantry motion and dynamic multi-leaf 
collimation.(9) Patients with cervical cancer who were treated with IMRT have reported 
improved target volume coverage which also allowed for dose escalation while 
reducing the radiation dose to organ at risk (OAR).(10) Additional studies have shown 
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contradictory information suggesting no dosmietric or clinical benefit with selected 
OAR sparing when IMRT was used.(11, 12)The ability to offer improved coverage while 
sparing OAR may allow for a superior therapeutic effect of VMAT when compared to 
3D-CRT. Taking this into consideration and the contrasting published results, this 
study may help to determine the better dosimetric option at our institution. 
 
The incidence and severity of radiation toxicity are multifactorial. These factors include 
the volume of tissue treated, dose received (Dmax and Dmean), and the technique for 
delivery of radiation therapy (3D-CRT versus IMRT) administered. Radiation Therapy 
Oncology Group (RTOG) 1203 compared IMRT to 3D-CRT radiotherapy in cervical 
cancer. The results showed significantly lower scores for gastrointestinal and urinary 
toxicity when using IMRT.(13) The study utilised the Expanded Prostate Cancer Index 
Composite (EPIC) to compare toxicities. EPIC is a questionnaire used to assess 
function and toxicity post-treatment. The mean EPIC bowel score declined 23.6 
points in the 3D-CRT group and 18.6 points in the IMRT group. The mean urinary 
score declined 10.4 points in the standard RT group and 5.6 points in the IMRT 
group. A larger decline from baseline suggested a poorer tolerance to treatment. 
RTOG 418 further suggested that IMRT was associated with lower rates of 
haematological toxicities with a lower V40 volume and higher rates of cisplatin use 
when compared to 3D-CRT.(14) 
 
With the advent of VMAT, issues regarding target definition, patient and target 
immobilisation, tissue deformation and reproducibility remain to be validated as 
additional factors that limit the OAR toxicity and treatment profiles.(12, 15, 16) To minimise 
the effects listed, specialised contouring guidelines for cervical cancer VMAT 
treatments have been published and implemented.(17) Additionally, with improved 
imaging localisation such as daily kilovoltage cone beam CT as compared to 
megavoltage orthogonal images, tumour localisation, deformation and reproducibility 
may be minimised.(18)    
 
Studies comparing conventional techniques to VMAT in the management of LACC are 
scarce and patient populations are small.(9) To date, there are no published articles in 
South Africa comparing 3D-CRT and VMAT. At GSH, VMAT, the accepted standard 
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of treatment internationally, (7,8,9) was added as a treatment option in May 2017. This 






Study aims and objectives: 
The aim of the study was to determine if VMAT is dosimetrically superior to 3D-CRT 
in the treatment of patients with LACC staged with the 2009 FIGO system (Appendix 
iv). The study included patients who were treated with VMAT for LACC at GSH 
between the period of May to December 2017. 
 
Study population: 
Formal sample size calculations were not performed. The number of patients was 
based on the feasibility of data collection and processing. The patients included were 
those treated radically for LACC with VMAT and concurrent chemotherapy, had a 
minimum age of 18 years and an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0-2. Patients not meeting these criteria were excluded from the 
study. Further exclusion criteria were connective tissue disease, poor performance 




Methods and Materials: 
This is a non-randomized comparative retrospective study. The medical records of all 
patients treated for LACC between the period of May to December 2017, meeting the 
inclusion criteria were reviewed. Data relating to age, stage and histological type were 
recorded. The patients’ VMAT radiation therapy plans were reviewed and the following 
information extracted: PTV D50%, Dmax, Dmean, conformity index (CI), homogeneity 
index(HI), treated volume (TV) , irradiated volume (IV) and OAR constraints; right and 
left femoral heads, bladder, bowel bag, rectum and bone marrow . For the purpose of 
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All patients were discussed at the combined Gynaecology clinic for decision making 
on treatment approach and patients suitable for concurrent chemotherapy and 
radiotherapy identified. These patients were prescribed a bowel prep with 
Senna/Docusate (stimulant/ laxative) and lactulose for two weeks prior to CT scan 
simulation and continued throughout treatment to aid with rectal emptying and 
reproducibility.  
 
On the day of treatment, a bladder protocol was followed: patients were asked to 
empty their bladders then drink 250cc of water, followed by a thirty-minute waiting 
period before the CT simulation scan was performed. This bladder protocol was 
repeated daily while on treatment to further improve bladder reproducibility. At GSH 
an inferior tumour limit is determined clinically, and the corresponding CT location 
marked to aid with lower limit delineation of tumours as MRI imaging is not routinely 
available for all patients. Patients were aligned using triangulation technique and 
scanned with intravenous and oral contrast in the supine position with knee rest and 
ankle stocks using 5 mm slices from T12 vertebral body to mid femur. On the scan 
date, tattooing of the skin with three-point pelvic markings were done to improve setup 
and minimise rotational errors during treatment. The final CT images were imported 
and contoured using the ECLIPSE planning system.  
 
The contouring guidelines(17, 19, 20) utilised at GSH generated a Clinical Target Volume 
(CTV). The CTV tumour comprised of the Gross Tumour Volume (GTV), cervix, uterus, 
parametrium and vagina. GTV delineation without MRI imaging was exceptionally 
difficult. As a result, it was assumed, once the cervix was contoured the disease was 
encompassed. Vaginal contouring was dependent on the extent of the disease. For 
minimal or no vaginal involvement, the upper half of the vagina was contoured. If the 
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upper half of vagina was involved with tumour, the upper two thirds was contoured 
and for extensive disease the entire vagina was contoured. Additionally, the 
mesorectum was included for Stage III B or extensive nodal involvement. The CTV 
nodes were generated using a 7-millimetre margin around the common, internal and 
external iliac vessels while using a 10-millimetre strip anterior to the sacrum. The 
obturator nodes were contoured with a 10-millimetre strip which connected the 
external and internal iliac vessels. Inguinal nodes with a seven mm expansion were 
contoured when there was round ligament and lower third of vagina involvement. The 
PTV tumour was created with a 1.5 cm expansion superior, anterior and posterior with 
1 cm in all other directions and PTV node was generated with a symmetric 7 mm 
expansion circumferentially. The OAR’s: right femoral head, left femoral head, bladder, 
bowel bag, bone marrow (23) and rectum, were also delineated using RTOG guidelines 
for the female pelvis.(20) The patient’s final plans were prescribed to a dose of 46.0 Gy 
to the mean volume in 23 fractions. 
 
EBRT plans were generated using the ECLIPSE system and optimisation criteria for 
VMAT technique. The plans were evaluated by the attending radiation oncologist 
based on the following criteria: PTV coverage ( ensuring the volume was adequately 
covered by the 95% isodose line), Dose Maximum (highest doses within the PTV 
which should be less than 107% for Dmax & D2%), Hot Spots ( a significant dose and 
corresponding volume (typically < 2cm3 & >107% dose) outside of the PTV), Monitor 
Units (MU) (accepted as less than 300MU per Gy for VMAT), Homogeneity Index, 
Conformity Index and OAR toxicities as defined by Quantec.(21) The plans were 
approved once all criteria were assessed and found to be within acceptable limits. The 
approved plans were then assessed by the Medical Physics department using quality 
assurance protocols. The Gamma Index was then evaluated before the plan was 
finally approved and treatment began. At GSH, a difference of 3% dose and a 3mm 
geometrical location between the planned dosimetric value and the generated doses 
on the treatment machines, are accepted.  All patients with LACC, treated radically, 
also received concurrent weekly cisplatin at a dose of 40 mg/m2. Chemotherapy 
should ideally be commenced on Mondays to ensure a synergistic effect with 
chemotherapy and radiotherapy. However, due to logistical issues, chemotherapy is 
given on a Thursday at GSH. Daily set up and verification was confirmed using offline 
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EPID verification. Additionally, brachytherapy commenced within the last week of 
EBRT using a 2D system prescribed to a Manchester point system. 
   
The patients selected for this study, who met the inclusion criteria, had a second plan 
generated using 3D-CRT technique for similar target volumes contoured for prior 
VMAT planning.  Senior radiographers, with experience in 3D-CRT cervical cancer, 
were used and blinded to previous radiotherapy plans with VMAT to reduce any 
possible bias. The plans were generated with mix energy beams, 18 MV and 6 MV 
photon energy, and no restrictions were placed on the number of fields or use of beam 
modifiers. At GSH, a four-field box was used for pelvic PTV structures with varying 
energies to ensure appropriate coverage and minimal toxicity to OAR. The final 
assessment and approval followed the criteria previously mentioned. Nine (20%) of 
the 3D-CRT plans were rejected as the criteria was not met. These included poor 
superior PTV coverage, OAR exceeded constraint and unacceptable hot spots. The 
plans were eventually accepted after suggested corrections were made. All 45 plans 
were again reviewed by an independent oncologist and once agreed, forwarded for 
Quality Assurance. External plan validation was also completed with the Im SureTM 
system which utilises an independent planning system to verify dose prescribed was 




Post plan assessment for both VMAT and 3D-CRT focused on recording PTV D2%, 
PTV D98%, PTV D50%, Dmax, Dmean, conformity index (CI), homogeneity index (HI), 
treated volume (TV), irradiated volume (IV) and patient separation, to fully assess 
treatment parameters.  
Treated Volume: The volume enclosed by an isodose surface, selected and specified 
by the radiation oncologist as being appropriate to achieve the purpose of 
treatment(22). At GSH the 95% isodose line was used. 
Irradiated Volume: The volume of tissue that receives a dose that is considered 
significant in relation to normal tissue tolerance(22). At GSH the 20% isodose was used. 
33 | P a g e  
 
Homogeneity Index:       PTV D2% – PTV D98%  (23) 
                                                PTV D50% 
 
Conformity Index:       Treated Volume  (23) 
                                       PTV Volume          
 
Patients’ OAR doses were recorded based on Quantec constraints; right and left 
femoral head maximum dose (Dmax<52 Gy)(24), bladder maximum dose (Dmax< 
65Gy)(24), small bowel (bowel bag) absolute volume (V45< 195cc )(24), bone marrow 





Statistical analysis was done using SPSS Version 25. Comparison of dosimetric 
values for 3D-CRT to VMAT was done using Wilcoxon Signed rank test as the initial 
Shapiro-Wilk test showed that the data was not normally distributed. Additionally, 
Mann Whitney U tests were used when comparing cervical cancer by stage. A p value 




Throughout the study patient privacy and confidentiality were strictly maintained. 
Anonymity was upheld by deidentifying the patients, the data collected was stored on 
the REDCap system under password protection and limited access. Ethical approval 
for the study was granted by the Human Research Ethics Committee of the Faculty of 
Health Sciences at the University of Cape Town. Reference Number – HREC REF: 

















       
       Patient Characteristics:  
 
       The mean age of the 45 patients was 52.8 ± 10.8 years.  
         
       The most common stage of disease identified was Stage IIB (n= 22) followed by    
       Stage IIIB (n= 25). The other stages are illustrated in Figure 1 
         
 The most common histology was Squamous Cell Carcinoma (n= 38) as seen in   





(A)        Histological Sub Classification        (B)              Cervical Cancer Stage   

















Figure 1: (A) Percentage distribution by Histological Type. 
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 Tumour Control: 
 
Table 1: Tumour Dosimetric Parameters for VMAT and 3D-CRT  
 
 VMAT 3D-CRT z p 
 Median IQR Median IQR   
PTV D2% (Gy) 47.8 47.5 – 48.0 47.7 47.4 – 48.3 -0.70 .483 
PTV D98% (Gy) 44.1 43.8 – 44.4 44.4 44.2 – 44.6 -2.97 .003 
PTV D50% (Gy) 46.0 46.0 – 46.1 46.6 46.1 – 46.9 -5.45 <.001 
Homogeneity Index 0.08 0.07 – 0.09 0.07 0.06 – 0.08 -1.47 .142 
D max (Gy) 49.2 48.9 – 49.5 48.1 47.7 – 48.6 -5.37 <.001 
D mean (Gy) 46.0 46.0 – 46.0 46.5 46.1 – 46.7 -5.17 <.001 
Treated Volume 95 
Isodose (cm3) 
1613.1 1471.4 – 1776.4 2230.3 1960.3 – 2457.9 -5.84 <.001 
PTV Volume (cm3) 1443.9 1331.8 - 1661.2 1443.9 1331.8 – 1661.2 -0.37 .715 
Conformity Index 1.09 1.06 – 1.12 1.49 1.44 – 1.59 -5.84 <.001 
Irradiated Volume 20 
Isodose(cm3)  
14618.1 12844 – 17943.2 11910.4 10652.2 – 14272.9 -5.77 <.001 
 
 
Table 1 examined the dosimetric values recorded for both treatment planning options. 
The median PTV volume for the patients treated was 1450 cm3 with Dmean favouring 
VMAT and a Dmax value favouring 3D-CRT. Additionally, PTV D2% was reviewed, which 
is considered a volume assigned to a maximum dose rather than a point dose, no 
statistical difference was found between 3D-CRT and VMAT.  
The conformity index for VMAT showed a lower median value when compared to 3D-
CRT while the improved homogeneity index associated with 3D-CRT was deemed 
statistically insignificant. Dosimetric assessment also showed approximately a 600 
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Organs at risk: 
VMAT displayed lower median doses when compared to 3D-CRT for both the right 
and left femoral head (Table 2). Figure 2 compared the relative volume of bone marrow 
receiving 40 Gy, showing a 2 times larger volume affected with 3D-CRT as compared 
to VMAT. Figure 3 compared the volume of bowel receiving a dose of 45 Gy and 
showed a median volume 200 cm3 greater with 3D-CRT than that recorded for VMAT. 





                                                                                                                                                                  
 






Figure 2: Box and Whisker                                      Figure 3: Box and Whisker   
plot comparing Bone Marrow                                 plot comparing Bowel Bag  
relative volume at 40Gy.                                         absolute volume at 45 Gy. 
                                                                                                                             
                                                                                                              
Median bladder Dmax was lower for 3D-CRT when compared to VMAT (Table 2). All 
OAR dosimetric values are seen in Table 2. 
  
Rectum, V50< 50 as per Quantec was 0 as the maximum dose on both plan groups 
were less than 50Gy. As such, comparitive statistical analysis was done using  
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VMAT  3D-CRT 
p 
Median IQR Median IQR 
Right Femoral Head (Dmax)  45.6 44.8- 46.8 46.6 46.1- 47.3 <.001 
Left Femoral Head (Dmax) 45.4 44.0- 46.2 46.8 45.7 - 47.4 <.001 
Bladder (Dmax) 48.3 47.9- 48.7 47.4 47.0 - 47.9 <.001 
Bowel Bag (Vol cm3) 182.3 129.3- 250.2 411.3 342.1 - 541.4 <.001 
Bone Marrow (Vol %) 19.1 14.9- 24.9 38.7 33.9 - 43.2 <.001 
Rectum (Vol %) 
 





Sub Group Analysis 
         
        When comparing Stage IIB to IIIB cancer groups, statistically signifcant differences 
were only found for VMAT Treated Volume 95 Isodose (U = 83, p = .010), 3D-CRT 
Treated Volume 95 Isodose (U = 70, p = .003) and PTV Volume (U = 83, p = .010). 
Table 3. No difference was noted for OAR dosimetry.  
 
 
Table 3: Comparison of statistically significant volumes between 3D-CRT and 
VMAT between Stage IIB and Stage IIIB. 
 
 
 Stage IIB Stage IIIB  p 
 Median IQR Median IQR   
       
VMAT Treated 
Volume 
1558.5 1461.23-1693.83 1754.70 1571.50-1993.30  .01 
3D Treated Volume  2188.6 1940.5-2340.03 2473.00 2309.90-2616.70  .003 
PTV Volume 1429.10 1295.10-1579.25 1658.10 1439.2-1862.7  .01 










The aim of this study focused on determining the dosimetrically superior EBRT option 
in the management of LACC at Groote Schuur Hospital, South Africa. To date, no 
similar studies have been done in South Africa comparing 3D-CRT to VMAT in the 
management of LACC. Most institutions with the capability to offer IMRT have done 
so with little local evidence or dosimetric proof of superiority. 3D-CRT remains the 
preferred treatment reference, to which all inverse planning options are compared 
when managing LACC.(25, 26) This study examined dosimetric values for OAR and 
assessed tumour dosimetry between 3D-CRT and VMAT to determine the superior 
option. 
 
Both 3D-CRT and VMAT showed appropriate dose coverage of the PTV. This 
coverage was deemed appropriate once the 95% isodose line encompassed the PTV. 
Additionally, the PTV Dmax and Dmean were found to be within an acceptable range as 
outlined in ICRU guidelines. (18) Further quantitative analysis of the plans showed 
VMAT having a superior, statistically significant conformity index compared to 3D-CRT 
(Table 1). Similar results were presented in the study done by Guy JB et al. in 2016 
comparing the dosimetrically superior option in LACC (9). Conformity index values 
closer to one suggests a more conformal distribution of higher doses as represented 
by TV. As radiotherapy moves toward greater precision, improved conformity is 
essential in tumour dose escalation(27) and minimizing high dose exposure to OAR.  
 
One of the major goals of radiotherapy is to deliver the maximum prescribed dose to 
a selected target volume uniformly, thus increasing the likelihood of tumour control. 
The homogeneity index, defined as the uniformity of dose distribution in the target 
volume, gives a numerical representation of this distribution. The homogeneity index 
between both methods of treatment were numerically different, indicating a small 
benefit towards 3D-CRT (Table 1). However, the value was not deemed statistically 
significant. At GSH, a homogeneity index less than 0.1 is accepted, which was 
achieved in both EBRT options.  
 
It has been suggested that IMRT offers superior OAR sparing in gynaecological 
malignancies.(28)  Similar findings in this study have supported this. OAR toxicity may 
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be affected by maximum dose as seen with the right femoral head, left femoral head 
and bladder, while volume dependant doses may affect organs such as bowel bag 
and bone marrow. Small bowel toxicity, as determined for bowel bag contours suggest 
a < 10 % Grade 3 toxicity for late effects and acute effects when V45Gy< 195 cm3.(17) 
The 3D-CRT median dose from this study revealed a value of 411.3 cm3 receiving 
45Gy while 182.3 cm3 for VMAT (Table 2 and Figure 3). Mell et al suggested a 
correlation between this dosimetric value and clinical symptoms tending to less acute 
and chronic symptoms when smaller volumes are exposed to similar doses.(29) Rectal 
dose comparisons also showed a more favourable dosimetric value for VMAT and as 
seen in RTOG 1203 a possible decrease in clinical toxicity.(30) 
 
Bone marrow contouring guidelines and dose constraints(31) have been well 
documented in cervical cancer patients. Clinical toxicity, secondary to bone marrow 
suppression, with EBRT appears to have a greater clinical impact when combined with 
concurrent chemotherapy as opposed to EBRT alone.(6) At GSH, this was noted in 
previous observational studies which altered the timely delivery of EBRT, especially in 
patients receiving concurrent chemotherapy. In the study population, the 3D-CRT 
patients’ median absolute volume receiving 40 Gy was twice that of VMAT (Table 2 
and Figure 2), considerably increasing the risk of Grade 2 and greater bone marrow 
toxicity. Bone marrow toxicity secondary to EBRT may result in delayed treatments 
which are in turn associated with poorer outcomes. In a study done by Girinsky et al. 
in 1993 the results showed when treatment exceeded 52 days, loss of local control 
and overall survival, was approximately 1% per day. (32)   
 
While VMAT was superior in limiting OAR dose constraints to most organs contoured, 
3D-CRT offered a reduced maximum dose to the bladder (Table 2). This result is 
contradictory to similar studies including Lin. Y et al. whose research documented 
lower bladder doses in a meta-analysis of cervical cancer treatment with IMRT.(33) It 
has been postulated that limited prioritisation for the bladder contoured in the 
optimisation software used by staff at GSH may be the reason for the difference in 
values. Both VMAT and 3D-CRT bladder max doses were within Quantec (17) 
constraints and it was difficult to determine the extent of clinical impact of these 
differences. 
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VMAT can reduce the TV by improving the conformity index. It also limits the OAR 
toxicity by allowing multiple beam entry points as it rotates around a patient avoiding 
OAR contours. This sparing effect has led to an increase in lower doses from multiple 
small fields. The IV, represents that volume of tissue irradiated by a dose that is 
clinically significant. This study revealed a significantly larger IV with VMAT, when 
compared to 3D-CRT (Table 1). Concern regarding secondary malignancies with 
increased integral dose as represented by IV has been studied extensively and most 
studies suggest integral dose is not a good estimator of quantifying cancer 
induction.(34)    
 
Lastly, sub-group analysis (Table 3) also revealed no statistically significant increase 
in OAR dosimetric values in Stage IIB vs IIIB cervical cancer when treated with either 
3D-CRT or VMAT. The significant volume differences are based on unique guidelines 
used for Stage IIIB which includes contouring of the mesorectum and vagina 
depending on degree of involvement. This data suggests that while Stage IIIB does 
result in larger contoured PTV tumour volumes, the OAR dosimetric values were 






This study is subject to limitations, including the retrospective nature and small sample 
size. Additionally, the dosimetric data gathered represent numerical values, which 
were compared against Quantec(17) guidelines to determine the possibility of clinical 
complications. These guidelines, while not extensively validated for VMAT, have been 
the backbone to which dosimetric values are compared to minimise clinical OAR 
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CONCLUSION 
       
Minimising toxicities while optimising tumour treatment is essential in the successful 
management of LACC. The data analysed for the investigated study population 
showed dosimetric benefit of VMAT over 3D-CRT in the management of LACC with 
improved OAR sparing. Improved OAR sparing with lower doses to the femoral heads, 
bowel bag and bone marrow, as seen with VMAT planning, will possibly reduce both 
early and late toxicities. VMAT also offered comparable tumour coverage and 
dosimetry, equally homogenous dose distribution, with the added benefit of improved 
conformity and possible dose escalation. Maintaining and improving tumour dosimetry 
with a reduction in toxicity, allows for better compliance with treatment which is integral 
in improving outcomes.  It is the hope of the authors that this study will provide support 
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